CD90 Promotes Gastric Cancer Progression by Regulating SLC1A5-Mediated Glutamine Metabolism Through YY1

IF 4.9 2区医学 Q1 ONCOLOGY

Cancer Science Pub Date : 2026-06-02 Epub Date: 2026-03-31 DOI:10.1111/cas.70377

Zihua Zhou, Siyi Liu, Chenyu Zhang, Jun Deng, Lin Liang, Yanhong Zhou

{"title":"CD90 Promotes Gastric Cancer Progression by Regulating SLC1A5-Mediated Glutamine Metabolism Through YY1","authors":"Zihua Zhou, Siyi Liu, Chenyu Zhang, Jun Deng, Lin Liang, Yanhong Zhou","doi":"10.1111/cas.70377","DOIUrl":null,"url":null,"abstract":"<p>CD90 (THY1) is a cell surface glycoprotein that plays a crucial role in the occurrence and development of various malignant tumors. It affects tumor cell proliferation, metastasis, angiogenesis, stem cell characteristics, and energy metabolism. CD90 is an important biomarker for many malignant tumors and is closely related to tumor prognosis. However, the role and specific mechanisms of CD90 in glutamine metabolism in gastric cancer (GC) cells remain incompletely understood. In this study, we report that CD90 affects glutamine metabolism in GC cells through SLC1A5, ultimately promoting GC progression. Mechanistically, CD90 promotes the binding of YY1 to the SLC1A5 promoter, enhances the transcriptional activity of the SLC1A5 promoter, and increases its transcriptional level. This, in turn, affects SLC1A5-mediated glutamine metabolism and ferroptosis in GC cells, ultimately facilitating GC progression. Our results suggest that CD90 plays an important role in regulating glutamine metabolism in GC cells, providing important experimental evidence for elucidating the pathogenesis of GC.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"117 6","pages":"1748-1765"},"PeriodicalIF":4.9000,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70377","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.70377","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

CD90 (THY1) is a cell surface glycoprotein that plays a crucial role in the occurrence and development of various malignant tumors. It affects tumor cell proliferation, metastasis, angiogenesis, stem cell characteristics, and energy metabolism. CD90 is an important biomarker for many malignant tumors and is closely related to tumor prognosis. However, the role and specific mechanisms of CD90 in glutamine metabolism in gastric cancer (GC) cells remain incompletely understood. In this study, we report that CD90 affects glutamine metabolism in GC cells through SLC1A5, ultimately promoting GC progression. Mechanistically, CD90 promotes the binding of YY1 to the SLC1A5 promoter, enhances the transcriptional activity of the SLC1A5 promoter, and increases its transcriptional level. This, in turn, affects SLC1A5-mediated glutamine metabolism and ferroptosis in GC cells, ultimately facilitating GC progression. Our results suggest that CD90 plays an important role in regulating glutamine metabolism in GC cells, providing important experimental evidence for elucidating the pathogenesis of GC.

Abstract Image

查看原文本刊更多论文

CD90通过YY1调控slc1a5介导的谷氨酰胺代谢促进胃癌进展

CD90 （THY1）是一种细胞表面糖蛋白，在多种恶性肿瘤的发生发展中起着至关重要的作用。它影响肿瘤细胞的增殖、转移、血管生成、干细胞特性和能量代谢。CD90是许多恶性肿瘤的重要生物标志物，与肿瘤预后密切相关。然而，CD90在胃癌（GC）细胞谷氨酰胺代谢中的作用和具体机制尚不完全清楚。在本研究中，我们报道CD90通过SLC1A5影响GC细胞的谷氨酰胺代谢，最终促进GC进展。从机制上讲，CD90促进YY1与SLC1A5启动子结合，增强SLC1A5启动子的转录活性，提高其转录水平。这进而影响slc1a5介导的谷氨酰胺代谢和GC细胞中的铁下垂，最终促进GC的进展。我们的研究结果提示CD90在胃癌细胞中调节谷氨酰胺代谢中发挥重要作用，为阐明胃癌的发病机制提供了重要的实验证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Science 医学-肿瘤学

自引率

3.50%

发文量

406

审稿时长

2 months

期刊介绍： Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.